Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians

JAMA - Journal of the American Medical Association

Volumn 314, Issue 2, 2015, Pages 170-180

  Benetos, Athanase ^a   Rossignol, Patrick ^a,b   Cherubini, Antonio ^c   Joly, Laure ^a   Grodzicki, Tomasz ^d   Rajkumar, Chakravarthi ^e   Strandberg, Timo E ^f,g   Petrovic, Mirko ^h  

^a UNIVERSITÉ DE LORRAINE   (France)

^b INI CRCT   (France)

^c INRCA   (Italy)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF OULU   (Finland)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BISOPROLOL; CARVEDILOL; DILTIAZEM; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; PERINDOPRIL; PLACEBO; SIMVASTATIN;

AGED; AGING; ARTERIAL STIFFNESS; ARTICLE; ATRIAL FIBRILLATION; CARDIOEMBOLIC STROKE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COGNITION; DIABETES MELLITUS; DRUG WITHDRAWAL; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMAN; HYDRATION; HYPERTENSION; INTENTION TO TREAT ANALYSIS; META ANALYSIS (TOPIC); PERSONALIZED MEDICINE; POLYPHARMACY; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RURAL POPULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WHITE COAT HYPERTENSION; AGE; BLOOD PRESSURE; DRUG EFFECTS; FEMALE; MALE; PRACTICE GUIDELINE;

AGE FACTORS; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; FRAIL ELDERLY; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; MALE; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC;

EID: 84937460136     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7517     Document Type: Article

References (87)

1. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular disease. Circulation. 2003;107:2864-2869.
2. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? Circulation. 2001;103(9): 1245-1249.
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34(28):2159-2219.
4. Alagiakrishnan K, Juby A, Hanley D, TymchakW, Sclater A. Role of vascular factors in osteoporosis. J Gerontol A Biol Sci Med Sci. 2003;58(4):362-366.
5. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia. Neurobiol Aging. 2000;21(1):49-55.
6. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women. Hypertension. 2005;46(2):280-286.
7. Benetos A, Thomas F, Bean KE, Pannier B, Guize L. Role of modifiable risk factors in life expectancy in the elderly. J Hypertens. 2005;23(10):1803-1808.
8. National Institute on Aging, National Institutes of Health. Global Health and Aging. NIH Publication no. 11-7737.Washington, DC:World Health Organisation; 2011.
9. Organisation for Economic Cooperation and Development. Health at a glance 2009: OECD indicators. http://www.oecd.org/health/healthsystems/ 44117530.pdf. Accessed April 19, 2015.
10. Berrut G, Andrieu S, Araujo de Carvalho I, et al. Promoting access to innovation for frail old persons. J Nutr Health Aging. 2013;17(8): 688-693.
11. Fried LP, Tangen CM,Walston J, et al. Frailty in older adults. J Gerontol A Biol Sci Med Sci. 2001;56 (3):M146-M156.
12. Studenski S, Perera S, al Patelet K. Gait speed and survival in older adults. JAMA. 2011;305(1): 50-58.
13. Baitar A, Van Fraeyenhove F, Vandebroek A, et al. Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. J Geriatr Oncol. 2013;4(1):32-38.
14. Romero-Ortuno R, Soraghan C. A frailty instrument for primary care for those aged 75 years or more. BMJ Open. 2014;4(12):e006645.
15. Abellan van Kan G, Rolland Y, Bergman H, et al. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging. 2008;12(1):29-37.
16. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
17. Bulpitt CJ, Beckett N, Peters R, et al. Does white coat hypertension require treatment over age 80? Hypertension. 2013;61(1):89-94.
18. Peters R, Beckett N, Fagard R, et al. Increased pulse pressure linked to dementia. J Hypertens. 2013;31(9):1868-1875.
19. Peters R, Beckett N, Beardmore R, et al: Modelling cognitive decline in the Hypertension in the Very Elderly Trial [HYVET] and proposed risk tables for population use. PLoS One. 2010;5(7): e11775.
20. Peters R, Beckett N, Burch L, et al. The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010;39(5):609-616.
21. Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension. BMJ. 2012;344:d7541.
22. Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people. BMC Med. 2015;13:78.
23. Kostis JB. Treating hypertension in the very old. N Engl J Med. 2008;358(18):1958-1960.
24. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5): 507-520.
25. Mattila K, HaavistoM, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old. Br Med J (Clin Res Ed). 1988;296(6626):887-889.
26. AskariM, Kiely DK, Lipsitz LA. Is pulse pressure a predictor of cardiovascular complications in a frail elderly nursing home population? Aging Clin Exp Res. 2004;16(3):206-211.
27. Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J AmGeriatr Soc. 2007;55(3):383-388.
28. Molander L, Lövheim H, Norman T, Nordström P, Gustafson Y. Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J AmGeriatr Soc. 2008;56(10):1853-1859.
29. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults. Arch Intern Med. 2012;172(15):1162-1168.
30. Rastas S, Pirttil? T, Viramo P, et al. Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc. 2006;54(6):912-918.
31. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA. 2000;284(4):465-471.
32. MullerM, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of hypertension in the oldest old? Hypertension. 2014;63(3):433-441.
33. Lipsitz LAA. A 91-year-old woman with difficult-to-control hypertension. JAMA. 2013;310 (12):1274-1280.
34. Benetos A, Gautier S, Labat C, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects. J AmColl Cardiol. 2012;60(16): 1503-1511.
35. Bejan-Angoulvant T, Saadatian-Elahi M,Wright JM, et al. Treatment of hypertension in patients 80 years and older. J Hypertens. 2010;28(7):1366-1372.
36. Benetos A, Labat C, Rossignol P, et al Treatment with multiple blood pressure medicines, achieved blood pressure, and mortality in older nursing home residents. JAMA Intern Med. 2015;175 (6):989-995.
37. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3-15.
38. Blacher J, Halimi JM, Hanon O. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol.2014;28(1):1-9.
39. National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults, August 2011. http://www.nice.org.uk/guidance/cg127/resources/guidance-hypertension-pdf. Accessed January 25, 2015.
40. AronowWS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J AmSoc Hypertens. 2011;5(4):259-352.
41. Cherubini A, Oristrell J, Pla X. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011; 171(6):550-556.
42. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Arch Intern Med. 2010; 170(18):1648-1654.
43. Fried TR, O'Leary J, Towle V, . Health outcomes associated with polypharmacy in community-dwelling older adults. J AmGeriatr Soc. 2014;62(12):2261-2272.
44. Mannucci PM, Nobili A. Multimorbidity and polypharmacy in the elderly. Intern Emerg Med. 2014;9(7):723-734.
45. Onder G, Bonassi S, Abbatecola AM, et al. High prevalence of poor quality drug prescribing in older individuals. J Gerontol A Biol Sci Med Sci. 2014;69 (4):430-437.
46. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-351.
47. PetrovicM, van der Cammen T, Onder G. Adverse drug reactions in older people. Drugs Aging. 2012;29(6):453-462.
48. Van Pottelbergh G, Van Heden L, Mathe? C, Degryse J. Methods to evaluate renal function in elderly patients. Age Ageing. 2010;39(5):542-548.
49. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009; 41(2):67-76.
50. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 2004;57 (1):6-14.
51. Hutchison LC, O'Brien CE. Changes in pharmacokinetics and pharmacodynamics in the elderly patient. J Pharm Pract. 2007;20(1):4-12. doi: 10.1177/0897190007304657
52. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103-107.
53. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10): 1045-1051.
54. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J AmGeriatr Soc. 2012;60(4):616-631.
55. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151(9):1825-1832.
56. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Int J Clin Pharmacol Ther. 2008;46(2):72-83.
57. O' Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218.
58. Dalleur O. Screening tools for the assessment of prescribing in older patients. http://www.farm.ucl.ac.be/cfcl/Theses/Dalleur/Dalleur-Thesis-2013.pdf. Accessed April 19, 2015.
59. ThoenesM, Spirk D, Böhm M, et al. Treatment of hypertension in the elderly. J Hum Hypertens. 2013;27(2):131-137.
60. Aguado A, L?pez F, Miravet S, et al. Hypertension in the very old. BMC Geriatr. 2009;8 (9):16.
61. Hiitola PK, Enlund H, Sulkava RO, Hartikainen SA. Changes in the use of cardiovascular medicines in the elderly aged 75 years or older. J Clin Pharm Ther. 2007;32(3):253-259.
62. Benetos A, Buatois S, Salvi P, et al. Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over. J Hypertens. 2010;28(1):41-50.
63. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum. JAMA. 2005;294(4):466-472.
64. Bromfield SG, Bowling CB, Tanner RM, et al. Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. J Clin Hypertens (Greenwich). 2014;16(4):270-276.
65. Amati F, Dubé JJ, Shay C, Goodpaster BH. Separate and combined effects of exercise training and weight loss on exercise efficiency and substrate oxidation. J Appl Physiol (1985). 2008;105(3):825-831.
66. Thomas DR. Loss of skeletal muscle mass in aging. Clin Nutr. 2007;26(4):389-399.
67. Sparling PB, Howard BJ, Dunstan DW, Owen N. Recommendations for physical activity in older adults. BMJ. 2015;350:h100.
68. Abellan van Kan G, Rolland Y, Houles M, et al. The assessment of frailty in older adults. Clin Geriatr Med. 2010;26(2):275-286.
69. Hirdes JP, Ljunggren G, Morris JN, et al. Reliability of the interRAI suite of assessment instruments. BMC Health Serv Res. 2008;8:277.
70. Van Den Noortgate N, PetrovicM. The importance of a geriatric approach in medicine. Acta Clin Belg. 2009;64(1):7-10.
71. Fusco D, Lattanzio F, TosatoM, et al. Development of CRIteria to assess appropriate medication use among elderly complex patients (CRIME) project. Drugs Aging. 2009;26(suppl 1): 3-13.
72. van der Cammen TJ, Rajkumar C, Onder G, Sterke CS, PetrovicM. Drug cessation in complex older adults. Age Ageing. 2014;43(1):20-25.
73. Ellis G, Whitehead MA, O'Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev. 2011;7(7):CD006211.
74. Onder G, Lattanzio F, Battaglia M, et al. The risk of adverse drug reactions in older patients. Curr Drug Metab. 2011;12(7):647-651.
75. Lampela P, Hartikainen S, Lavikainen P, Sulkava R, Huupponen R. Effects of medication assessment as part of a comprehensive geriatric assessment on drug use over a 1-year period. Drugs Aging. 2010;27 (6):507-521.
76. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy. JAMA Intern Med. 2015;175(5):827-834.
77. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia. JAMA. 2014;312(11):1136-1144.
78. Kalyanasundaram A, Lincoff AM. Managing adverse effects and drug-drug interactions of antiplatelet agents. Nat Rev Cardiol. 2011;8(10): 592-600.
79. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease. Lancet. 2009;373(9678):1849-1860.
80. Lip GY, Lane DA. Stroke prevention in atrial fibrillation. JAMA. 2015;313(19):1950-1962.
81. Camm AJ, Lip GYH, De Caterina R, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012; 33(21):2719-2747.
82. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults. J AmGeriatr Soc. 2014;62(5):857-864.
83. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes. JAMA. 2015;313(6):603-615.
84. Sinclair AJ, Paolisso G, Castro M, et al. European DiabetesWorking Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. DiabetesMetab. 2011;37(suppl 3):S27-S38.
85. Sinclair A, Dunning T, Rodriguez-Ma?as L. Diabetes in older people. Lancet Diabetes Endocrinol. 2015;3(4): 275-285.
86. Benetos A, Novella JL, Guerci B, et al. Pragmatic diabetes management in nursing homes. J AmMed Dir Assoc. 2013;14(11):791-800.
87. Moorhouse P, Mallery LH. Palliative and therapeutic harmonization. J AmGeriatr Soc. 2012; 60(12):2326-2332.